Search clinical trials for: Hemophilia children

Total 32618 results

CSL Behring

Enrolling by invitation

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

Hemophilia B

United States
Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B (Paradigm9)

Haemophilia B

China
CSL Behring

Active, not recruiting

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

Hemophilia B

United States, Belgium, Netherlands, Denmark, Germany, Ireland, Sweden, United Kingdom
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period (ACTIVATE-KidsT)

Pediatric Pyruvate Kinase Deficiency | Pediatric Hemolytic Anemia

United States, Spain, Denmark, Turkey, Netherlands, Czechia, United Kingdom, Germany, Canada, Switzerland
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

Severe Hemophilia A | Moderate Hemophilia A

Brazil, Germany, Italy, Spain, United States, Turkey, United Kingdom, Tunisia, Canada, Hungary, Morocco, Serbia
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Agios Pharmaceuticals, Inc.

Active, not recruiting

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Pyruvate Kinase Deficiency

United States, Spain, Japan, Canada, United Kingdom, Korea, Republic of, Ireland, Thailand, Italy, Turkey, Denmark, Brazil, France, Germany, Netherlands, Switzerland
Sangamo Therapeutics

Active, not recruiting

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX (LTFU)

Hemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis II

United States
Pfizer

Active, not recruiting

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Hemophilia A | Hemophilia B

United States, Canada, Spain, Australia, Korea, Republic of, Taiwan, Brazil, Italy, Japan, Turkey, Germany, United Kingdom, Saudi Arabia, France, Sweden, Belgium, Greece, Israel
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (pathfinder™6)

Congenital Bleeding Disorder | Haemophilia A

United States, Spain, Australia, France, Thailand, Italy, Malaysia, Austria, Greece, Japan, Taiwan, Canada, Israel, Algeria, Argentina, Bulgaria, Germany, Romania
The Cleveland Clinic
RTI International

Completed

Pomalidomide for the Treatment of Bleeding in HHT (PATH-HHT)

Telangiectasia, Hereditary Hemorrhagic

United States
BioMarin Pharmaceutical

Enrolling by invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) (GENEr8-LTE)

Hemophilia A

United Kingdom, United States
Andrea Doria
Beijing Children's Hospital, Baxalta US Inc.

Completed

Imaging of Arthropathy in Boys With Hemophilia in China

Hemophilia

China
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
Swedish Orphan Biovitrum

Active, not recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (A-MORE)

Hemophilia A

Spain, Germany, Czechia, Italy, Estonia, Finland, Greece, Netherlands, Saudi Arabia, Slovenia, Sweden, Switzerland, United Kingdom
Takeda

Active, not recruiting

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Hemophilia A

China
Hoffmann-La Roche

Active, not recruiting

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (HAVEN 5)

Hemophilia A

China, Thailand, Hong Kong, Malaysia
BioMarin Pharmaceutical

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3)

Hemophilia A

United States, Australia, Taiwan, Brazil
Novo Nordisk A/S

Completed

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (paradigm™5)

Congenital Bleeding Disorder | Haemophilia B

United States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
Pfizer

Active, not recruiting

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Hemophilia A | Hemophilia B

United States, Spain, Canada, China, Korea, Republic of, Hong Kong, Serbia, Taiwan, Turkey, France, Oman, Saudi Arabia, Japan, India, South Africa, Mexico, Croatia, Italy, Bulgaria, Russian Federation
Pfizer

Active, not recruiting

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 (034OLE)

Sickle Cell Disease

United States, Lebanon, United Kingdom, Oman, Turkey, Canada, Egypt, Kenya, France, Italy, Netherlands
Bayer

Completed

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Hemophilia A

China
Novo Nordisk A/S

Completed

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B (paradigm™6)

Congenital Bleeding Disorder | Haemophilia B

Spain, United Kingdom, Australia, Taiwan, France, Malaysia, United States, Austria, Canada, Israel, Japan, Thailand, Algeria, Argentina
Novo Nordisk A/S

Active, not recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors (explorer7)

Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Spain, Korea, Republic of, India, Australia, United Kingdom, Russian Federation, Poland, Ukraine, Thailand, Mexico, United States, Turkey, Japan, South Africa, Serbia, France, Croatia, Denmark, Algeria, Bulgaria, Malaysia, Portugal, Slovaki... and more
Bioverativ, a Sanofi company

Active, not recruiting

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (XTEND-ed)

Hemophilia A

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom
Genzyme, a Sanofi Company

Active, not recruiting

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX (ATLAS-OLE)

Hemophilia

China, Hungary, Turkey, Canada, Korea, Republic of, United States, Australia, Denmark, France, Germany, India, Ireland, Israel, Italy, Japan, Malaysia, South Africa, Taiwan, Ukraine, United Kingdom
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Completed

A Study of ADVATE in People With Hemophilia A in India

Hemophilia A

India
Pfizer

Active, not recruiting

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (AFFINE)

Hemophilia A

Spain, Taiwan, Australia, United States, Japan, France, Turkey, Germany, Korea, Republic of, United Kingdom, Saudi Arabia, Canada, Greece, Sweden, Brazil, Italy
Spark Therapeutics

Completed

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

Hematologic Diseases | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Gene Therapy | Blood Coagulation Disorder | Gene Transfer | Adeno-Associated Virus (AAV) | Factor VIII (FVIII) | Factor VIII (FVIII)... and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

Severe Hemophilia A

Canada, United States, United Kingdom, Belgium, Australia, Austria, Brazil, France, Germany, Israel, Italy, South Africa, Spain, Turkey
Bioverativ, a Sanofi company

Completed

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (XTEND-Kids)

Hemophilia A

Turkey, Australia, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Pfizer

Active, not recruiting

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Hemophilia A

United States
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
Genzyme, a Sanofi Company

Active, not recruiting

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Hemophilia

Canada, Italy, Turkey, Spain, United States, India
Swedish Orphan Biovitrum
Cerner Enviza

Active, not recruiting

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B (B-MORE)

Hemophilia B

Czechia, Greece, Ireland, Italy, Norway, Saudi Arabia, Spain, Sweden, United Kingdom
Baxalta now part of Shire

Active, not recruiting

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

Hemophilia B

United States
American Thrombosis and Hemostasis Network
Genentech, Inc.

Active, not recruiting

ATHN 7: Hemophilia Natural History Study (ATHN 7)

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without Inhibitor

United States
American Thrombosis and Hemostasis Network
Takeda

Active, not recruiting

ATHN 9: Severe VWD Natural History Study

Von Willebrand Diseases

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)

Hemophilia A

Czechia, Switzerland, Denmark, Canada, Australia, Austria, France, United Kingdom, Italy, Sweden, Belgium, Brazil, China, Colombia, Greece, Hungary, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain
Spark Therapeutics

Active, not recruiting

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Hemophilia A

United States, Canada, Australia
Spark Therapeutics

Completed

A Gene Transfer Study for Hemophilia A

Hemophilia A

United States, Australia, Canada, Israel, Thailand
Emory University
Genentech, Inc.

Withdrawn

Emicizumab PUPs and Nuwiq ITI Study

Hemophilia A

United States
BioMarin Pharmaceutical

Active, not recruiting

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (BMN 270-301)

Hemophilia A

United States, Taiwan, United Kingdom, Australia, Israel, Belgium, Brazil, France, Germany, Italy, Korea, Republic of, South Africa, Spain
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
CSL Behring

Completed

Dose Confirmation Trial of AAV5-hFIXco-Padua

Hemophilia B

United States
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
Daiichi Sankyo, Inc.

Completed

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Deep Vein Thrombosis | Venous Thromboembolism

Spain, United States, United Kingdom, India, France, Canada, Italy, Lebanon, Turkey
Children's Hospital Los Angeles
Grifols Biologicals, LLC

Active, not recruiting

Preventing Inhibitor Recurrence Indefinitely (PRIORITY)

Hemophilia A | Immune Tolerance

United States
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Hemophilia A

Spain, United States, Denmark, Italy, Taiwan, Malaysia, Belgium, Thailand, Turkey, Austria, Bulgaria, Canada, Finland, France, Germany, Hong Kong, Hungary, Korea, Republic of, Netherlands, Norway, Singapore, Ukraine, United Kingdom

Search clinical trials for: Hemophilia children

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations